Scholar Rock Holding Co. (NASDAQ:SRRK) CFO Sells $287,605.47 in Stock

Scholar Rock Holding Co. (NASDAQ:SRRK) CFO Edward H. Myles sold 7,809 shares of Scholar Rock stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $36.83, for a total transaction of $287,605.47. Following the sale, the chief financial officer now owns 140,740 shares in the company, valued at $5,183,454.20. This represents a 5.26 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Scholar Rock Price Performance

Shares of NASDAQ SRRK opened at $37.70 on Friday. The stock has a market capitalization of $3.53 billion, a PE ratio of -16.04 and a beta of 0.50. The business has a fifty day moving average price of $41.81 and a two-hundred day moving average price of $28.51. Scholar Rock Holding Co. has a fifty-two week low of $6.76 and a fifty-two week high of $46.98. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in SRRK. GAMMA Investing LLC increased its stake in shares of Scholar Rock by 51.8% in the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock valued at $34,000 after purchasing an additional 269 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Scholar Rock by 1.0% in the third quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company’s stock valued at $310,000 after buying an additional 379 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Scholar Rock by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,895 shares of the company’s stock valued at $25,000 after acquiring an additional 514 shares during the last quarter. Amalgamated Bank raised its stake in Scholar Rock by 30.6% during the fourth quarter. Amalgamated Bank now owns 2,643 shares of the company’s stock worth $114,000 after acquiring an additional 620 shares in the last quarter. Finally, Global Retirement Partners LLC lifted its holdings in shares of Scholar Rock by 584.7% in the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock worth $39,000 after acquiring an additional 766 shares during the last quarter. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on SRRK shares. Wedbush reaffirmed an “outperform” rating and set a $47.00 price target on shares of Scholar Rock in a report on Wednesday, January 29th. Truist Financial raised their price objective on shares of Scholar Rock from $36.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, November 25th. Finally, HC Wainwright increased their price target on shares of Scholar Rock from $40.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Scholar Rock has an average rating of “Buy” and a consensus target price of $40.43.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.